Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Clinical trial NCT06440850 · RECRUITING

Trial details

NCT number: NCT06440850
Sponsor: City of Hope Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Gland Follicular Carcinoma Thyroid Gland Oncocytic Carcinoma Thyroid Gland Papillary Carcinoma

Start date: 2024-07-15
Primary completion: 2026-11-22
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.